Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs show promise in diabetes management, offering heart and kidney benefits, but also highlight the need for vigilance regarding new health risks.

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Now used for type 2 diabetes, new study shows GLP-1 drugs helped people with type 1 keep blood glucose levels in a healthy range while also losing weight.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

A new oral drug may be able to treat type 2 diabetes and obesity without impacting muscle mass as an alternative to GLP-1 drugs such as Ozempic, the results of a phase 1 clinical trial suggest.

Here’s a roundup of numbers from the last week of HR news — including the percentage of managers who use AI to help determine ...

The pilot study found that GLP-1 agonists reduced monthly migraine days by almost half. The authors hypothesized that the drug lowers migraine frequency by reducing intracranial pressure.

Obesity drugs were first approved to treat type 2 diabetes, but there’s a growing movement to test them in type 1 diabetes, too. Research presented Monday at a large diabetes meeting showed ...

A new potential drug treatment for people with type 2 diabetes and obesity lowers blood sugar and increases fat burning.